

Scott F Huntington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/991403/publications.pdf>

Version: 2024-02-01

87
papers

1,416
citations

361296

20
h-index

360920

35
g-index

87
all docs

87
docs citations

87
times ranked

2177
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	0.6	248
2	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. <i>Lancet Haematology</i> , 2015, 2, e408-e416.	2.2	158
3	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. <i>Blood Advances</i> , 2020, 4, 2192-2201.	2.5	68
4	Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. <i>Journal of Clinical Oncology</i> , 2017, 35, 3417-3424.	0.8	61
5	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 175, 829-840.	1.2	59
6	Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. <i>Journal of Clinical Oncology</i> , 2015, 33, 1467-1474.	0.8	56
7	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	0.6	53
8	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	0.6	50
9	Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. <i>Blood</i> , 2018, 131, 818-821.	0.6	45
10	Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3307-3314.	0.8	37
11	Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. <i>Oncologist</i> , 2021, 26, 120-132.	1.9	37
12	Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 2245-2253.	2.5	36
13	Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. <i>Blood</i> , 2020, 136, 1946-1955.	0.6	32
14	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. <i>Blood Advances</i> , 2020, 4, 1615-1623.	2.5	32
15	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. <i>Cancer</i> , 2019, 125, 4241-4251.	2.0	28
16	Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. <i>Blood Cancer Journal</i> , 2018, 8, 55.	2.8	26
17	Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 3763-3771.	2.0	25
18	Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. <i>Prostate</i> , 2017, 77, 437-445.	1.2	24

#	ARTICLE	IF	CITATIONS
19	Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 2880-2887.	0.6	23
20	Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1119-1128.	0.8	23
21	Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2020, 61, 397-408.	0.6	19
22	Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. <i>Cancer</i> , 2017, 123, 3754-3762.	2.0	18
23	Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 1195-1203.e4.	0.6	18
24	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 994-1002.	2.5	18
25	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. <i>Leukemia and Lymphoma</i> , 2017, 58, 982-985.	0.6	16
26	Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. <i>Haematologica</i> , 2018, 103, e462-e465.	1.7	15
27	Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1178-1187.	0.6	15
28	Healthcare expenses for treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 641-650.	1.0	14
29	The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. <i>Blood Advances</i> , 2018, 2, 2681-2690.	2.5	13
30	Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1112-1117.	0.5	12
31	Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. <i>Cancer</i> , 2019, 125, 4084-4095.	2.0	10
32	Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. <i>Blood</i> , 2020, 136, 13-14.	0.6	10
33	Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. <i>Cancer</i> , 2018, 124, 4211-4220.	2.0	9
34	RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 3181-3187.	0.6	9
35	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0184747.	1.1	9
36	The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. <i>American Journal of Hematology</i> , 2018, 93, 874-881.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population. <i>Blood</i> , 2016, 128, 3574-3574.	0.6	6
38	Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 211-219.	2.3	6
39	Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3387-3394.	0.6	5
40	Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). <i>Blood</i> , 2015, 126, 873-873.	0.6	5
41	Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. <i>Blood Advances</i> , 2022, 6, 376-385.	2.5	5
42	Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. <i>Blood Advances</i> , 2022, 6, 3339-3342.	2.5	5
43	High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. <i>Journal of Clinical Oncology</i> , 2016, 34, 4307-4309.	0.8	4
44	Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2033441.	2.8	4
45	B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma. <i>JAAD Case Reports</i> , 2021, 8, 89-92.	0.4	4
46	Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4686-4690.	2.5	4
47	Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1766-1770.	0.6	4
48	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110434.	1.1	3
49	Barriers and solutions to improve access for chimeric antigen receptor therapies. <i>Immunotherapy</i> , 2022, 14, 741-753.	1.0	3
50	Negative Studies in Cancer Research. <i>JAMA Oncology</i> , 2016, 2, 865.	3.4	2
51	Overall survival based on oncologist density in the United States: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0250894.	1.1	2
52	Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2777-2784.	0.6	2
53	Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. <i>Blood</i> , 2018, 132, 3580-3580.	0.6	2
54	Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey. <i>Blood</i> , 2021, 138, 3020-3020.	0.6	2

#	ARTICLE	IF	CITATIONS
55	First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood, 2021, 138, 43-43.	0.6	2
56	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	0.6	2
57	Primary anti-infective prophylaxis during routine treatment of lymphoma in the United States: A large real-world cohort analysis.. Journal of Clinical Oncology, 2021, 39, 268-268.	0.8	1
58	Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood, 2019, 134, 4748-4748.	0.6	1
59	Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood, 2020, 136, 51-52.	0.6	1
60	Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood, 2016, 128, 1188-1188.	0.6	1
61	Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood, 2016, 128, 4773-4773.	0.6	1
62	Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood, 2016, 128, 4790-4790.	0.6	1
63	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood, 2015, 126, 3285-3285.	0.6	1
64	Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. Blood, 2018, 132, 5384-5384.	0.6	1
65	Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes. Blood, 2020, 136, 2-3.	0.6	1
66	Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. Blood, 2020, 136, 21-22.	0.6	1
67	Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015â€“2020. Leukemia and Lymphoma, 2022, 63, 1180-1190.	0.6	1
68	Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum, 2019, 3, pkz030.	1.4	0
69	Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1066.	3.4	0
70	Reply to H.J.A. Adams et al. Journal of Clinical Oncology, 2019, 37, 853-854.	0.8	0
71	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia and Lymphoma, 2021, 62, 1-10.	0.6	0
72	Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model.. Journal of Clinical Oncology, 2021, 39, e18850-e18850.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. <i>Blood</i> , 2016, 128, 394-394.	0.6	0
74	Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States. <i>Blood</i> , 2017, 130, 675-675.	0.6	0
75	Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. <i>Blood</i> , 2018, 132, 3538-3538.	0.6	0
76	Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. <i>Blood</i> , 2019, 134, 2188-2188.	0.6	0
77	Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 252-259.	0.9	0
78	Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19057-e19057.	0.8	0
79	Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies. <i>Blood</i> , 2021, 138, 4026-4026.	0.6	0
80	Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. <i>Blood</i> , 2021, 138, 4092-4092.	0.6	0
81	Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. <i>Blood</i> , 2021, 138, 182-182.	0.6	0
82	Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 38-38.	0.8	0
83	Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
84	Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. <i>Blood</i> , 2020, 136, 44-45.	0.6	0
85	Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 43-44.	0.6	0
86	Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
87	Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7554-7554.	0.8	0